Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

8 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Role of 18F-FDG PET/CT in Posttreatment Evaluation of Anal Carcinoma.
Houard C, Pinaquy JB, Mesguich C, Henriques de Figueiredo B, Cazeau AL, Allard JB, Laharie H, Bordenave L, Fernandez P, Vendrely V. Houard C, et al. Among authors: laharie h. J Nucl Med. 2017 Sep;58(9):1414-1420. doi: 10.2967/jnumed.116.185280. Epub 2017 Mar 9. J Nucl Med. 2017. PMID: 28280225 Free article.
Locoregional relapses in the ACCORD 12/0405-PRODIGE 02 study: Dosimetric study and risk factors.
Meillan N, Orthuon A, Chauchat P, Atlani D, Bouche O, Chaulin B, David C, Deberne M, Debrigode C, Kao W, Keller A, Laharie H, Lamezec B, Lemanski C, Magné N, Mahé MA, Mere P, Moureau-Zabotto L, Peiffert D, Pointreau Y, Quéro L, Racadot S, Roca S, Sargos P, Servagi S, Tang E, Vendrely V, Doyen J, Huguet F. Meillan N, et al. Among authors: laharie h. Radiother Oncol. 2021 Aug;161:198-204. doi: 10.1016/j.radonc.2021.06.006. Epub 2021 Jun 16. Radiother Oncol. 2021. PMID: 34144078
Gemcitabine plus nab-paclitaxel until progression or alternating with FOLFIRI.3, as first-line treatment for patients with metastatic pancreatic adenocarcinoma: The Federation Francophone de Cancérologie Digestive-PRODIGE 37 randomised phase II study (FIRGEMAX).
Rinaldi Y, Pointet AL, Khemissa Akouz F, Le Malicot K, Wahiba B, Louafi S, Gratet A, Miglianico L, Laharie H, Bouhier Leporrier K, Thirot Bidault A, Texereau P, Coriat R, Terrebonne E, Gouttebel MC, Malka D, Bachet JB, Lepage C, Taieb J; PRODIGE 37 Investigators/Collaborators. Rinaldi Y, et al. Among authors: laharie h. Eur J Cancer. 2020 Sep;136:25-34. doi: 10.1016/j.ejca.2020.05.018. Epub 2020 Jul 2. Eur J Cancer. 2020. PMID: 32623182 Clinical Trial.
[Radiation therapy of benign diseases. What's new eight years after?].
Van Houtte P, Roelandts M, Devriendt D, Minsat M, Laharie H, Kantor G. Van Houtte P, et al. Among authors: laharie h. Cancer Radiother. 2005 Nov;9(6-7):427-34. doi: 10.1016/j.canrad.2005.09.004. Epub 2005 Oct 10. Cancer Radiother. 2005. PMID: 16219478 Review. French.
Overall and progression-free survival with cabazitaxel in metastatic castration-resistant prostate cancer in routine clinical practice: the FUJI cohort.
Rouyer M, Oudard S, Joly F, Fizazi K, Tubach F, Jove J, Lacueille C, Lamarque S, Guiard E, Balestra A, Droz-Perroteau C, Fourrier-Reglat A, Moore N; FUJI Investigators. Rouyer M, et al. Br J Cancer. 2019 Dec;121(12):1001-1008. doi: 10.1038/s41416-019-0611-6. Epub 2019 Nov 13. Br J Cancer. 2019. PMID: 31719685 Free PMC article.